Identifying new biomarkers for Alzheimer's disease through endosomal dysfunction
Targeting Endosomal dysfunction as a new source of biomarkers for Alzheimer's disease
This study is looking at how problems with certain cell processes might affect Alzheimer's disease, with the goal of finding new ways to track the disease's progress and help create better treatments for people living with it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11001132 on NIH RePORTER |
What this research studies
This research investigates the role of endosomal dysfunction in Alzheimer's disease (AD) to develop new biomarkers that reflect cellular changes associated with the condition. By focusing on the endosomal trafficking defects linked to AD, the study aims to identify specific proteins in cerebrospinal fluid that could serve as indicators of disease progression. The approach includes genetic and cell biology studies, particularly examining the retromer complex and its impact on neuronal health. This could lead to improved diagnostic tools and accelerate the development of targeted therapies for AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk for developing the condition.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new diagnostic biomarkers that enhance early detection and monitoring of Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in identifying biomarkers related to endosomal dysfunction in Alzheimer's, suggesting a potential for success in this novel approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Alves Simoes Spassov, Sabrina — Columbia University Health Sciences
- Study coordinator: Alves Simoes Spassov, Sabrina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.